MA38657A1 - Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer - Google Patents

Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer

Info

Publication number
MA38657A1
MA38657A1 MA38657A MA38657A MA38657A1 MA 38657 A1 MA38657 A1 MA 38657A1 MA 38657 A MA38657 A MA 38657A MA 38657 A MA38657 A MA 38657A MA 38657 A1 MA38657 A1 MA 38657A1
Authority
MA
Morocco
Prior art keywords
cancer
combination
treatment
mitotic agent
imidazopyridazine derivative
Prior art date
Application number
MA38657A
Other languages
English (en)
Inventor
Gerhard Siemeister
Antje Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48578942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38657(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38657A1 publication Critical patent/MA38657A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une combinaison comprenant un inhibiteur de la mps-1 kinase et un inhibiteur de la mitose. La présente invention concerne également l'utilisation de ladite combinaison pour le traitement d'un cancer, en particulier du cancer du pancréas, d'un glioblastome, du cancer de l'ovaire, d'un carcinome pulmonaire non à petites cellule, du cancer du sein et/ou du cancer gastrique.
MA38657A 2013-06-13 2014-06-11 Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer MA38657A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171818 2013-06-13
PCT/EP2014/062133 WO2014198776A1 (fr) 2013-06-13 2014-06-11 Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA38657A1 true MA38657A1 (fr) 2018-05-31

Family

ID=48578942

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38657A MA38657A1 (fr) 2013-06-13 2014-06-11 Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer

Country Status (17)

Country Link
US (1) US20160175306A1 (fr)
EP (1) EP3007698A1 (fr)
JP (1) JP2016521740A (fr)
KR (1) KR20160018749A (fr)
CN (1) CN105392484A (fr)
AP (1) AP2015008915A0 (fr)
AU (1) AU2014280224A1 (fr)
CA (1) CA2914995A1 (fr)
CL (1) CL2015003606A1 (fr)
EA (1) EA028800B1 (fr)
HK (1) HK1222341A1 (fr)
MA (1) MA38657A1 (fr)
MX (1) MX2015017245A (fr)
PH (1) PH12015502756A1 (fr)
SG (1) SG11201510034QA (fr)
TN (1) TN2015000544A1 (fr)
WO (1) WO2014198776A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613927A (en) * 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CN104284896B (zh) * 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
WO2014020041A1 (fr) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□

Also Published As

Publication number Publication date
EA028800B1 (ru) 2017-12-29
AU2014280224A1 (en) 2016-01-07
CN105392484A (zh) 2016-03-09
CL2015003606A1 (es) 2016-08-12
EA201600014A1 (ru) 2016-06-30
CA2914995A1 (fr) 2014-12-18
JP2016521740A (ja) 2016-07-25
US20160175306A1 (en) 2016-06-23
WO2014198776A1 (fr) 2014-12-18
SG11201510034QA (en) 2016-01-28
TN2015000544A1 (en) 2017-04-06
KR20160018749A (ko) 2016-02-17
EP3007698A1 (fr) 2016-04-20
AP2015008915A0 (en) 2015-12-31
HK1222341A1 (zh) 2017-06-30
MX2015017245A (es) 2016-07-20
PH12015502756A1 (en) 2016-03-14

Similar Documents

Publication Publication Date Title
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
MA39034B1 (fr) Composés de quinoline sélectivement substitués
TN2018000044A1 (en) Pd-l1 ("programmed death-ligand 1") antibodies
MA41013B1 (fr) Compositions comprenant des souches bactériennes
MX2017012613A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
MA42471A (fr) Compositions comprenant des souches bactériennes
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
GEP20217330B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
TR201902525T4 (tr) Janus ile alakalı kinazların (jak) inhibitörleri olarak bir veya daha fazla ilave ajan ile pirolo [2,3-d]pirimidin türevlerinin kombinasyonu.
BR112015027951A2 (pt) arilquinazolinas
EA201691916A1 (ru) Биарильные ингибиторы киназы
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
MA38656A1 (fr) Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
MX2023012628A (es) Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales.
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
WO2013106747A3 (fr) Méthodes et compositions pour le traitement et le diagnostic du cancer de la thyroïde
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
EP4286853A3 (fr) Compositions présentant une grande spécificité pour l'évaluation du cancer de l'ovaire
MA34952B1 (fr) Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme